Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.

The triad of sterile pyogenic arthritis, pyoderma gangrenosum and acne is known by the acronym of PAPA syndrome. It is a rare autosomal dominant disease of early onset.

The treatment of pyoderma gangrenosum is challenging as there is often only partial response to systemic glucocorticosteroids and immunosuppressive therapies.

We report the rapid and lasting response of pyoderma gangrenosum to the targeted treatment with the recombinant human interleukin-1 receptor antagonist (rHuIL-1Ra) anakinra in a patient with PAPA syndrome.

"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra."
Br J Dermatol. 2009 Aug 10; Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (Hubmed.org)



Related:
Ineffective Dermatoses - Pyoderma Gangrenosum

Ineffective Dermatoses - Pyoderma gangrenosum Signs - Symptoms , Disease information , Diognosis ,treatment & Images. this part of your post is hidden.

Pyoderma gangrenosum

I admitted this lady with a diagnosis of pyoderma gangrenosum . it is a chronic ulcerating rash that occurs from a specific type of dysfunction in one's immune system, which causes necrosis and eating away of the skin to various degrees ...

Infliximab effectively treats pyoderma gangrenosum

research in this month's issue of gut reports that infliximab at a dose of 5 mg/kg shows promising results in the treatment of pyoderma gangrenosum.